These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

512 related articles for article (PubMed ID: 11277827)

  • 1. Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995-1998: Opportunities for prevention in the conjugate vaccine era.
    Robinson KA; Baughman W; Rothrock G; Barrett NL; Pass M; Lexau C; Damaske B; Stefonek K; Barnes B; Patterson J; Zell ER; Schuchat A; Whitney CG;
    JAMA; 2001 Apr; 285(13):1729-35. PubMed ID: 11277827
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Nuorti JP; Whitney CG;
    MMWR Recomm Rep; 2010 Dec; 59(RR-11):1-18. PubMed ID: 21150868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine.
    Lexau CA; Lynfield R; Danila R; Pilishvili T; Facklam R; Farley MM; Harrison LH; Schaffner W; Reingold A; Bennett NM; Hadler J; Cieslak PR; Whitney CG;
    JAMA; 2005 Oct; 294(16):2043-51. PubMed ID: 16249418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of childhood vaccination on racial disparities in invasive Streptococcus pneumoniae infections.
    Flannery B; Schrag S; Bennett NM; Lynfield R; Harrison LH; Reingold A; Cieslak PR; Hadler J; Farley MM; Facklam RR; Zell ER; Whitney CG;
    JAMA; 2004 May; 291(18):2197-203. PubMed ID: 15138241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preventing pneumococcal disease among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Advisory Committee on Immunization Practices
    MMWR Recomm Rep; 2000 Oct; 49(RR-9):1-35. PubMed ID: 11055835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Invasive pneumococcal disease in young children before licensure of 13-valent pneumococcal conjugate vaccine - United States, 2007.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2010 Mar; 59(9):253-7. PubMed ID: 20224541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease--United States, 1998-2003.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2005 Sep; 54(36):893-7. PubMed ID: 16163262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study.
    Waight PA; Andrews NJ; Ladhani SN; Sheppard CL; Slack MP; Miller E
    Lancet Infect Dis; 2015 May; 15(5):535-43. PubMed ID: 25801458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changing epidemiology of invasive pneumococcal disease among White Mountain Apache persons in the era of the pneumococcal conjugate vaccine.
    Lacapa R; Bliss SJ; Larzelere-Hinton F; Eagle KJ; McGinty DJ; Parkinson AJ; Santosham M; Craig MJ; O'Brien KL
    Clin Infect Dis; 2008 Aug; 47(4):476-84. PubMed ID: 18627249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway.
    Steens A; Bergsaker MA; Aaberge IS; Rønning K; Vestrheim DF
    Vaccine; 2013 Dec; 31(52):6232-8. PubMed ID: 24176490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Invasive Pneumococcal Disease Following the Introduction of 13-Valent Conjugate Vaccine in Children in New York City From 2007 to 2012.
    Farnham AC; Zimmerman CM; Papadouka V; Konty KJ; Zucker JR; Nattanmai GV; Jose S; Rosen JB
    JAMA Pediatr; 2015 Jul; 169(7):646-52. PubMed ID: 25938798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Invasive pneumococcal disease: Clinical outcomes and patient characteristics 2-6 years after introduction of 7-valent pneumococcal conjugate vaccine compared to the pre-vaccine period, the Netherlands.
    Wagenvoort GH; Sanders EA; Vlaminckx BJ; Elberse KE; de Melker HE; van der Ende A; Knol MJ
    Vaccine; 2016 Feb; 34(8):1077-85. PubMed ID: 26778420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recommendations for the prevention of Streptococcus pneumoniae infections in infants and children: use of 13-valent pneumococcal conjugate vaccine (PCV13) and pneumococcal polysaccharide vaccine (PPSV23).
    American Academy of Pediatrics Committee on Infectious Diseases
    Pediatrics; 2010 Jul; 126(1):186-90. PubMed ID: 20498180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Laboratory surveillance of invasive pneumococcal disease in Australia in 2001 to 2002--implications for vaccine serotype coverage.
    Watson M; Bayley K; Bell JM; Gilbert GL; Hogg G; Keil AD; Krause V; Murphy D; Roche P; Smith HV; Stewart MG; Stylianopoulos J; Turnidge J
    Commun Dis Intell Q Rep; 2003; 27(4):478-87. PubMed ID: 15508501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Experience with pneumococcal polysaccharide conjugate vaccine (conjugated to CRM197 carrier protein) in children and adults.
    Durando P; Faust SN; Fletcher M; Krizova P; Torres A; Welte T
    Clin Microbiol Infect; 2013 Oct; 19 Suppl 1():1-9. PubMed ID: 24083785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term Impact of a "3 + 0" Schedule for 7- and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in Australia, 2002-2014.
    Jayasinghe S; Menzies R; Chiu C; Toms C; Blyth CC; Krause V; McIntyre P
    Clin Infect Dis; 2017 Jan; 64(2):175-183. PubMed ID: 27986682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Invasive Pneumococcal Disease Among Immunocompromised Persons: Implications for Vaccination Programs.
    Shigayeva A; Rudnick W; Green K; Chen DK; Demczuk W; Gold WL; Johnstone J; Kitai I; Krajden S; Lovinsky R; Muller M; Powis J; Rau N; Walmsley S; Tyrrell G; Bitnun A; McGeer A;
    Clin Infect Dis; 2016 Jan; 62(2):139-47. PubMed ID: 26354970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Are current recommendations for pneumococcal vaccination appropriate for Western Australia? The Vaccine Impact Surveillance Network--Invasive Pneumococcal Study Group.
    Med J Aust; 2000 Oct; 173(S2):S36-40. PubMed ID: 11062805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of conjugate pneumococcal vaccines on the changing epidemiology of pneumococcal infections.
    Zangeneh TT; Baracco G; Al-Tawfiq JA
    Expert Rev Vaccines; 2011 Mar; 10(3):345-53. PubMed ID: 21434802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccination, underlying comorbidities, and risk of invasive pneumococcal disease.
    Yildirim I; Shea KM; Little BA; Silverio AL; Pelton SI;
    Pediatrics; 2015 Mar; 135(3):495-503. PubMed ID: 25647674
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.